Guidelines References

Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014 May;133(5):1270–7.

Chow SK. Management of chronic urticaria in Asia: 2010 AADV consensus guidelines. Asia Pac Allergy. 2012 Apr;2(2):149–60.

Godse KV, Zawar V, Krupashankar D, Girdhar M, Kandhari S, Dhar S, et al. Consensus statement on the management of urticaria. Indian J Dermatol. 2011 Sep–Oct;56(5):485–9.

Godse K, Rajagopalan M, Girdhar M, Kandhari S, Shah B, Chhajed PN, et al. Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients. Indian Dermatol Online J. 2016 Jan–Feb;7(1):6–11.

Grattan CE, Humphreys F. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol. 2007 Dec;157(6):1116–23.

Hide M, Hiragun T. Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries. Allergol Int. 2012 Dec;61(4):517–27.

National Institute for Health and Care Excellence (NICE). Omalizumab for previously treated chronic spontaneous urticaria. Technology appraisal guidance [TA339]. 2015. Available at: https://www.nice.org.uk/guidance/ta339 (accessed April 2017).

Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015 Mar;45(3):547–65.

Société Française de Dermatologie. Consensus Conference: management of chronic urticaria. Wednesday 8 January 2003. Institut Pasteur-Paris, France. Recommendations (short version). Eur J Dermatol. 2003 Jul–Aug;13(4):385–92.

Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B. et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2017 revision and update. Allergy. 2018 Jul;73(7):1398–414.